Bioimpacts. 2018;8(3): 153-157. doi: 10.15171/bi.2018.17
PMID: 30211074        PMCID: PMC6128977


Enzyme replacement therapies: what is the best option?

Cited by CrossRef: 2

1- Safary A, Moniri R, Hamzeh-Mivehroud M, Dastmalchi S. Highly efficient novel recombinant L-asparaginase with no glutaminase activity from a new halo-thermotolerant Bacillus strain. Bioimpacts. 2018;9(1):15 [Crossref]
2- Buchinskaya N, Kostik M, Kolobova O, Melnikova L. How Not to Miss the Mild Forms of Mucopolysaccharidosis Type I in Patients With Articular Manifestations of the Disease?. Vopr sovr pediatr. 2019;17(6):473 [Crossref]

BioImpacts, as a peer-reviewed international journal, publishes all types of papers on bench-to-bedside translational aspects of pharmaceutical and biomedical sciences. As a "Publish Free" and "Access Free" journal, BioImpacts follows a constructive peer-review process with free editing service to benefit the scientific community worldwide.